|Laura Brown |
Dr Laura Brown is an independent pharmaceutical project management and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 16 years of experience of managing projects in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and Phoenix International. She is also co-author of two books on project management, including Pharmaceutical Project Management.
|G Steven Burrill |
G Steven Burrill has been instrumental to the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr Burrill is one of the original architects of the industry and one of its most avid and sustained developers. After spending 28 years with Ernst & Young, directing and co-ordinating the firm’s services to clients in the life sciences industries worldwide, he founded Burrill & Company in 1994, a life sciences merchant bank. He currently serves on the boards of directors of a number of life sciences companies including, Catalyst Biosciences, Depomed, Novadaq, Proventys, Targacept and XDx.
|Stephen Whitehead |
Stephen Whitehead joined the Association of the British Pharmaceutical Industry (ABPI) as Chief Executive in June 2011. He is the chief advocate for the research-based pharmaceutical industry in the UK. His priorities are to foster greater partnership working between the industry and the NHS, ensure reward for the industry’s investment in R&D to develop new medicines, and to encourage better uptake of innovative treatments in the NHS. He also strives for greater recognition of the contribution the pharmaceutical industry makes to patient health, and wants to foster a better understanding of how medicines are brought from bench to patient. He has a strong commitment to the pharmaceutical industry and earlier in his career spent ten years at Glaxo and Lilly.
|Antony Butler |
Antony Butler was Japan’s representative at PhRMA until the end of April 2006. Before joining PhRMA in 2001, he was vice-president for business development at Pharmacia (and Pharmacia & Upjohn), having served previously as vice-president for Japan, Europe and Latin America at the company. Mr Butler began his pharmaceutical career in 1966 at the Upjohn Company, joining its international division in 1975, for which he worked in Africa, Europe, Latin America, the US and Japan.
|Katrina Campion |
Katrina Campion is senior clinical research manager for GlaxoSmithKline in Australia and president and chair of ARCS Australia, a professional society for those who work in the therapeutics industry in the Asia Pacific region. She was elected to the ARCS board nearly 10 years ago and this is her fourth year as president. She has helped to shape ARCS’ strategic direction and been involved in the growth of this not-for-profit organisation for clinical research professionals. In her current role, she provides leadership and management of GSK’s clinical research activities in Australia and New Zealand.
|Dennis Gillings CBE |
Dr Dennis Gillings CBE began his industry career by providing statistical consulting and data management services to pharmaceutical clients in 1974 during his tenure as Professor of Biostatistics at the University of North Carolina at Chapel Hill. These activities grew to form Quintiles, which he founded in 1982 and is now the largest global provider of clinical trials and commercial marketing services to the pharma and biotechnology industry. With more than 30 years of experience in drug development applications and theory, Dr Gillings has provided expert consultation to numerous companies and health organizations, including the National Cancer Institute and the Institute of Medicine. He also was the founding chairman of the Association of Clinical Research Organizations.
|Trevor Jones CBE |
Professor Trevor Jones is a director of Allergan, Sigma-Tau, VeronaPharma, ReNeuron and Synexus. Between 1987 and 1994, he was a main board director of The Wellcome Foundation, where he was responsible for R&D. He is a founder member of the Medicines for Malaria Venture and in 2004 was appointed to the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health. He was previously a member of the UK Medicines Commission and director general of the Association of the British Pharmaceutical Industry.
|Jonathan Knowles |
Professor Jonathan Knowles, former head of group research and a member of the Executive Committee at Roche up to 2009, is a global opinion leader in personalised medicine. He was a member of the Board at Genentech for the last 13 years as well as a member of the Chugai Pharmaceuticals Board. He holds a Distinguished Professorship in Personalized Health Care at the Finnish Institute for Molecular Medicine, was appointed Professor of Translational Research at EPFL in Switzerland and has been appointed to a visiting chair at the University of Oxford. At the beginning of 2010, he joined the Board of Caris Life Sciences, and in May 2010 assumed the role of Caris’ chief scientific officer.
|Rolf Krebs |
Professor Rolf Krebs joined Bayer in Wuppertal in 1976 and became head of Bayer’s Worldwide Pharmaceutical R&D Department and head of the Pharma Sector R&D Coordination Committee in 1984. From 1986 to 1989 he was Vice-chairman of Bayer Italy, and in 1989 he became a managing partner at C H Boehringer Sohn and vice chairman of the board of managing directors at Boehringer Ingelheim. In 2001, he became chairman of the board of directors. From 1998 to 2000 he was president of EFPIA and from 2000 to 2002 he was president of the IFPMA. He is currently chairman of the supervisory board of Ganymed Pharmaceuticals, and Merck KgaA.
|Viren Mehta |
Dr Viren Mehta is the founder of Mehta Partners, an independent advisory firm to pharma and biotechnology companies worldwide. For over 20 years his work has focused on global strategic consulting as well as research for the investment industry. Prior to pioneering the in-depth science-driven valuation of the biopharma industry, Dr Mehta was a part of the strategic planning team of the international division at Merck & Co and earned a Doctor of Pharmacy at the University of Southern California, and an MBA from the University of California, Los Angeles.
|Phornvit Phacharintanakul |
Phornvit Phacharintanakul is chairman of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chairman of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Mr Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.
|Peter Pitts |
Peter Pitts is president of the Center for Medicine in the Public Interest. A former member of the US Senior Executive Service, from 2002 to 2004 Peter was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised the FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee consultant to the FDA’s Risk Communications Advisory Committee.
|Alison Messom |
Dr Alison Messom was elected last year as chairman of the board of the Institute of Clinical Research, a membership organisation for clinical research professionals who are are involved in all aspects of design, management and conduct of human clinical trials. She has been a member for 20 years and has detailed personal experience of directing global clinical trials, with operational experience in over 50 countries and line-management experience in over 30 countries. Currently senior director clinical operations for ICON Clinical Research, she provides leadership and management to a team of professionals in Europe and the Middle East. A molecular geneticist by training, Dr Messom has held leadership roles in a variety pharmaceutical companies and CROs, supporting clinical operations, data management, study start up, translational medicine, outsourcing and informatics.
|Robert Spiegel |
Dr Robert Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies, and serves as an advisor to Warburg Pincus. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. He is a Fellow of the American College of Physicians and has received numerous awards and fellowships including the NIH Biomedical Research Support Program Grant, Leukemia Society of America Fellowship, and the Mary Ellis Bell Prize of the University of Pennsylvania. He serves on the Boards of numerous biotechnology companies and non-profit organisations. He is an Associate Fellow in the University of Pennsylvania Center for Bioethics.
|Brian Tempest |
Dr Brian Tempest has worked in the Pharmaceutical Industry for the last 42 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Between 2009 and 2011 he was chairman of Indian investment bank Religare Capital Markets. Previously Dr Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net worth individuals on their strategy in Asia based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Dr Tempest is non-executive director of SRL, the largest Indian diagnostics company, Fortis Healthcare, and Glenmark Pharmaceuticals.